1-for-200, Then 1-for-40: Nasdaq's $1 Bid Rule Is Where the AI Selloff Reaches the Retail Account

Not one of the six issuers in this cluster sells artificial intelligence, and that is what makes the cluster diagnostic rather than thematic. Accuray sells radiosurgery systems, Jasper Therapeutics is a pre-revenue mast-cell biotech, Robo.ai builds electric vehicles, C3is owns dry bulk vessels, Solowin Holdings is a Hong Kong brokerage and Intrusion sells threat-intelligence software. What they share is a share price below Nasdaq's $1.00 minimum bid, and the cure clock that follows.

The consolidation ratios are a ranking of how far each quote had already fallen, because a bid price has to be restored to $1.00 for the cure to work and a bigger collapse demands a bigger ratio. C3is makes the point in one filing sequence: 1-for-40 in August, then 1-for-5 in November, a cumulative 200-for-1 in three months, with the same shareholders told twice. That is not a one-time administrative event; it is a company whose equity currency keeps changing denomination because the listing rule, not the business, is setting the price.

The timing also matters more than the trigger. Solowin's board approved its 200-for-1 on Oct. 2, Accuray's board approved its 40-for-1 on Oct. 28, and Intrusion's first 180-day cure period expired on Nov. 3, all before the Nov. 5 session that erased roughly $2.5 trillion of Nasdaq Composite market value. The selloff did not create the compliance wave. It raised the price of curing it, because a lower bid price requires a larger consolidation ratio to clear the same $1.00 threshold.

The mechanics are documented in Intrusion's Nov. 5 filing. Under Nasdaq Listing Rule 5550(a)(2), a closing bid below $1.00 for 30 consecutive business days starts a 180-calendar-day cure period; if that fails, a second 180-day period can be granted; and compliance is restored by closing at or above $1.00 for 10 consecutive business days, extendable to 20 under Rule 5810(c)(3)(H). Miss the deadline and staff issues a delisting determination, which the company can take to a Nasdaq Hearings Panel.

The arithmetic for a small holder is severe in a way that never shows up in an index. A 100-share position becomes 2.5 shares at Accuray, 3.33 at Jasper Therapeutics, 4 at Robo.ai and half a share at Solowin Holdings. The dollar value is unchanged and the round lot is not. Positions become odd lots, which sit outside the quote infrastructure that liquidity providers use for round lots, and the fractional remainder is settled in cash rather than carried, which is a taxable event on a depressed quote.

C3is handled it the other way in August, paying cash in lieu of fractional shares, and the OCC told members on Nov. 4 that cash would be paid in lieu of fractional shares for the Jasper Therapeutics consolidation. So the same wave runs through accounts two ways: some fractional entitlements get cashed out at the bottom of the tape, some get rounded up into positions too small to trade. Both outcomes land in the same place, a broker client account.

The clearest evidence that this wave is about financing rather than paperwork sits in Solowin Holdings's sequence. The board approved the 200-for-1 on Oct. 2, shareholders approved on Oct. 13, the company signed an at-the-market sales agreement with Chaince Securities on Oct. 22 against its existing shelf, split-adjusted trading began Oct. 29, and on Nov. 3 the chief financial officer and a director resigned. A cure that lands inside a registered resale is not housekeeping; it is the sequence for selling stock into a quote the exchange will accept.

Each of these companies is solving a bid-price problem with a tool that does not touch the actual problem. Accuray carried $42.3 million of cash against $136.0 million of debt into a September quarter with a $36.5 million operating loss and revenue down 7.9%, and the 40-for-1 makes the share count small enough to quote, not the balance sheet smaller enough to fund. Jasper Therapeutics held $7.3 million against a $60.3 million trailing burn, so its 30-for-1 reads as a financing step. Robo.ai has $2.1 million of cash against $95.8 million of equity that is mostly $83.0 million of intangibles.

The dilution consequence is already visible in the one issuer with a full year of comparable data. Accuray's weighted-average diluted share count rose from 118.9 million in the September 2025 quarter to 138.2 million a year later, a 16% increase delivered into a shrinking revenue base, and its trailing operating cash flow is negative $19.2 million. The 40-for-1 sits on top of that: fewer shares, each worth more, each easier to place, and each carrying a larger claim on the same business.

What would falsify the reading: a Nasdaq rule change that relaxes the cure or the bid-price standard, a rebound in AI credit that reopens the equity window for sub-$1 issuers, or a quarter in which a compliant quote is restored by price rather than by a split. The risk running the other way is equally concrete. If the post-split quotes hold, the wave is over and the odd-lot damage is a one-time event rather than a running cost carried by the retail base.

The investor takeaway is narrow but hard to ignore. The largest listed names in the AI complex repriced on macro factors that any analyst can model, while a group of companies with no AI exposure repriced on a listing rule that almost nobody models, and the second repricing reaches the smallest accounts in the market through odd lots and fractional cash rather than through index drawdowns. The damage from this selloff is not in the mega-cap tape, and it is not in the six issuers either, since their equity value did not change at all. It is in the denominational structure of the positions now sitting in $315 billion of retail client credit.